Launches uniquely formulated products NIXIT and JOINTFLEX
Bengaluru-based Strides Consumer Private Limited (SCPL) marked its footprint into the Northern markets of India, after successful expansion in southern and eastern regions. As part of its entry, SCPL has launched two distinct products, NIXIT, an oral Nicotine Replacement Therapy (NRT) and JOINTFLEX, a topical analgesic cream for joint care.
SCPL has two marquee investors – India Life Sciences Fund with ~74 per cent holdings and Strides Pharma Science (a listed company) with ~26 per cent. It aims to offer Indian consumers high quality and differentiated products inspired by the best of global products with Indian customisation.
NIXIT is a great tasting NRT Gum. NRT is the recommended first-line therapy by the WHO and US FDA which helps to quit smoking. NIXIT follows the three months step down the dosage schedule of NRT. At present, the NRT market is pegged at Rs 156 crore and projected to reach Rs 450 crore by 2023.
JOINTFLEX, a topical analgesic cream helps build healthy joints. Fortified with super ingredients GLUCOSAMINE and CHONDROITIN SULPHATE, it provides powerful, fast-acting and long-lasting pain relief.
Subodh Marwah, CEO, SCPL said, “Our expansion into the new geographic sphere testifies our vision to take our brand and products to every customer in the nation. Our products NIXIT and JOINTFLEX are based on advanced formulations with extensive research to ensure we cater to the requirements of every consumer.”